Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 158

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 2
Chunk 158
---
 agreement. The Rylaze, Vaxneuvance, Ohtuvayre and Capvaxive royalty rates are in the low single digits. Filspari has a fixed royalty rate of 9%. 

38

The following table represents revenue from intangible royalty assets by program (in millions):

(in millions)Q3 2025 Estimated Partner Product SalesEffective Royalty RateQ3 2025 Royalty RevenueQ3 2024 Estimated Partner Product SalesEffective Royalty RateQ3 2024 Royalty RevenueKyprolis$404.4 2.9 %$11.6 $405.4 2.9 %$11.6 Evomela9.5 20.0 %1.9 8.5 20.0 %1.7 Teriparatide injection(1)7.3 35.6 %2.6 8.6 27.9 %2.4 Rylaze 104.6 3.4 %3.6 98.8 3.9 %3.9 Filspari101.1 9.0 %9.1 35.6 9.0 %3.2 Vaxneuvance226.0 0.9 %2.0 239.0 0.6 %1.5 Ohtuvayre(2)135.8 2.0 %2.7 5.6 1.8 %0.1 Capvaxive244.0 1.3 %3.2 58.0 0.7 %0.4 Other107.3 3.3 %3.5 82.3 2.2 %1.8 Total$1,340.0 $40.2 $941.8 $26.6 

(in millions)YTD 2025 Estimated Partner Product SalesEffective Royalty RateYTD 2025 Royalty RevenueYTD 2024 Estimated Partner Product SalesEffective Royalty RateYTD 2024 Royalty RevenueKyprolis$1,168.4 2.1 %$25.1 $1,213.7 2.2 %$27.2 Evomela26.5 20.0 %5.3 29.5